Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment
Authors:
- 1 October 2021
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 22 (10) , e430-e434
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- An efficient basket trial designStatistics in Medicine, 2017
- Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examplesAnnals of Oncology, 2016
- Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive BiomarkerClinical Pharmacology & Therapeutics, 2016
- Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One StudyStatistics in Biopharmaceutical Research, 2016
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerJournal of Clinical Oncology, 2015
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsNew England Journal of Medicine, 2015
- Improving Clinical Trial Efficiency: Thinking outside the BoxAmerican Society of Clinical Oncology Educational Book, 2015
- Improving the Drug Development ProcessJAMA, 2014
- Biomarkers and surrogate end points—the challenge of statistical validationNature Reviews Clinical Oncology, 2010
- Clinical trials for predictive medicine: new challenges and paradigmsClinical Trials, 2010